Did Staar Surgical beat or miss consensus estimates last quarter?

What is the revenue and EPS growth rate for Staar Surgical year over year?

What is Staar Surgical's latest dividend and current dividend yield?

What were the key takeaways from Staar Surgical’s earnings call?

What were the key takeaways from Staar Surgical's earnings call?

What is Staar Surgical's gross profit margin?

What factors drove the changes in Staar Surgical's revenue and profit?

What does Staar Surgical do and what are its main business segments?

- **China Recovery Drives Growth**: 2025 in-market EVO ICL demand rebounded mid-single-digit, with 2026 targeting normalized distributor inventory and net sales growth.
- **U.S. Expansion Accelerates**: EVO's expanded age range adds 8M candidates, Q4 U.S. sales +18% YoY, driven by surgeon adoption of lens-based procedures.
- **Profitability Focus**: 2026 targets profitability with cost discipline, gross margin slightly lower due to Swiss manufacturing costs but offset by higher ASPs.
- **Innovation Momentum**: EVO+ launch in China with premium ASPs, Lioli injector rollout in EMEA, and Swiss manufacturing supporting supply chain resilience.

**【CEO Summary Section】**
- **2025 Transition and 2026 Growth Focus**: CEO Warren Foust emphasized 2025 as a year of transition, with 2026 targeting growth, profitability, and innovation. The company is stabilizing China operations, reducing costs, and scaling Swiss manufacturing.
- **China Recovery**: In-market EVO ICL demand rebounded mid-single-digit in 2025, despite distributor inventory challenges. 2026 expects improved net sales as inventory normalizes.
- **U.S. Expansion**: EVO's expanded age range (21-60) adds 8M potential candidates. Q4 2025 U.S. sales grew 18%, driven by surgeon adoption of lens-based procedures.
- **Innovation**: EVO+ launched in China with premium ASPs, and Lioli injector rolled out in EMEA. Swiss manufacturing to mitigate tariffs and support EVO+ supply.
- **Cost Discipline**: 2025 operating expenses reduced 8.2% YoY, targeting $225M annualized run rate in 2026.

**【CFO Financial Commentary】**
- **Q4 2025 Results**: Net sales $57.8M (+17.5% YoY), China sales $17.5M (+126% YoY). Gross margin 75.7% (vs. 64.7% YoY), driven by Swiss manufacturing and cost reductions.
- **Profitability Targets**: 2026 aims for profitability, with gross margin slightly lower due to Swiss inventory costs, offset by higher ASPs and efficiencies.
- **Cash Position**: $187.5M in cash, no debt. 2026 expects cash generation resumption in H2.

**【Q&A Key Highlights】**
- **China Inventory**: Stabilized at contractual levels, with weekly monitoring. Q1 2026 sees cautious optimism for in-market demand recovery.
- **U.S. Strategy**: Focus on high-margin EVO procedures, with 18% Q4 growth despite laser decline. "Highway 93" surgeon partnerships driving adoption.
- **EVO+ Premium**: Early demand shows ASP premium, with Swiss manufacturing scaling to meet demand.
- **Tariff Mitigation**: Swiss production avoids U.S.-China tariffs, supporting 2026 margin expansion.
- **Innovation Pipeline**: V5 and Lioli injector updates expected, with focus on first-in-man trials and regulatory milestones.

STAAR Surgical Company(STAA)-20260304-2025 Q4 Earnings call transcript

- **China Recovery on Track**: Q3 2025 sales to reflect 27.5M deferred order, stable in-market procedures
- **Tariff-Proof Supply Chain**: 300,000+ lenses pre-positioned in Switzerland, consignment model mitigates 2025 tariffs
- **Cost Optimization Progress**: $225M annual SG&A run rate on track, 9% ex-China sales growth
- **Gross Margin Improvement**: 70%+ in 2H2025, targeting 75-80% mid-term
- **Liquidity Management**: $222M cash, confident of >$140M trough, $150-175M year-end target

**【CEO Opening Remarks】**
- First-quarter revenue was $42.6 million, down 45% year-over-year due to China distributor inventory management. Ex-China sales grew 9%.
- 2025 strategic priorities: tariff mitigation, cost optimization, Switzerland manufacturing ramp-up, and EVO+ lens launch in China.
- Targeted $225M annualized SG&A run rate through workforce reductions, facility consolidation, and marketing efficiency improvements.
- China in-market ICL procedures were stable Q1 vs. Q1 2024, despite reported sales decline.

**【CFO Financial Update】**
- Q1 GAAP net loss: $26.4M (vs. $5.3M profit YoY). Non-GAAP EBITDA loss: $26.4M (vs. $5.3M profit YoY).
- Gross margin 65.8% (vs. 78.9% YoY), pressured by low U.S. manufacturing volumes and Swiss facility ramp costs.
- $22.7M restructuring charges included severance, lease impairments, and asset write-downs.
- Cash balance $222.8M (vs. $234.5M YoY). Expect cash to dip below $140M mid-year before rebounding.

**【Warren Faust - China Operations】**
- Mitigated 2025 China tariffs by:
  - Shifting 27.5M in consigned inventory to distributors
  - Pre-positioning 300,000+ lenses in Switzerland for 2026+ production
  - Completing Swiss facility validation by summer 2025
- EVO+ lens (V5) expected China approval Q3 2025 with premium pricing strategy
- China distributor inventory normalized by end-June 2025

**【Key Q&A Highlights】**
- **China Recovery**: Q3 2025 sales expected to reflect 27.5M deferred Q4 2024 order
- **Tariff Mitigation**: 2026+ production from Switzerland will eliminate U.S. origin tariffs
- **U.S. Strategy**: Rebalancing U.S. marketing spend with 11% YoY growth despite laser market decline
- **Gross Margin Outlook**: 70%+ in 2H2025, returning to 75-80% mid-term
- **Cash Flow**: Negative Q2-Q3, positive from Q4+ with $150-175M year-end cash target

STAAR Surgical (STAA)-7 May 25-2025 Q1 Earnings call transcript

- **China Dominance & Risk**: China sales (-13% Q4, $7.5M) weigh on FY24 results, with 2025 outlook ($75-125M) hinging on stimulus and consumer recovery.
- **Global Resilience**: Ex-China growth (+13% FY) driven by US (+15% FY), EMEA (+10% FY), and APAC (+14% FY).
- **2025 Financial Targets**: Ex-China sales +9-15%, gross margin 75%, and cash management to $150-175M by year-end.
- **Key Catalysts**: China stimulus, EVO Plus launch (mid-2025), and US Fast Lane expansion.
- **Risk Factors**: China macroeconomic uncertainty, inventory management, and competitive dynamics.

**【CEO Summary Section】**
- **2024 Fiscal Year Results**: Net sales of $314 million (-3% YoY), driven by a 13% decline in China due to weak consumer confidence. Ex-China sales grew 13% ($152 million), with 22% growth in the US and 9% in EMEA.
- **China Challenges**: Q4 China sales dropped 13% YoY to $7.5 million, with a $27.5 million shipment in December not recognized due to extended payment terms. Management expects China sales in 2025 to range from $75 million to $125 million, reflecting macroeconomic uncertainty.
- **Global Growth**: Americas (+22% Q4, +15% FY), EMEA (+9% Q4, +10% FY), and APAC (ex-China) (+20% Q4, +14% FY) offset China weakness. Fast Lane accounts in the US grew 45% FY24.
- **2025 Outlook**: Ex-China sales expected to grow 9-15%, while China sales depend on stimulus and consumer recovery. EVO Plus launch in China mid-2025 could provide ASP upside.

**【CFO Financial Commentary】**
- **2024 Financials**: GAAP net loss of $20.2 million (vs. $21.3 million net income FY23), with gross margin at 76.3% (-210bps YoY). Q4 gross margin impacted by $3.9 million COGS from China shipments.
- **2025 Guidance**: 
  - **Revenue**: $40M/Q1-Q2, with China rebound in H2. Full-year sales range $480-540M (vs. $314M FY24).
  - **Gross Margin**: 75% FY25 (low 70s H1, mid-high 70s H2).
  - **OpEx**: G&A $20-27M/Q, S&M $22-30M/Q, R&D $11-15M/Q.
  - **Cash**: End FY24 at $230.5M, targeting $150-175M FY25 after managing AR and CapEx ($15M FY25).

**【Q&A Highlights】**
- **China Inventory Management**: Distributors have elevated inventory, with minimal China sales expected in H1. Revenue recognition tied to payment terms; $27.5M shipment to be recognized by Q3 2025.
- **Competitive Landscape**: Eyebright's entry in China seen as minimal threat; STAAR maintains 3M+ implant history vs. Eyebright's limited clinical experience.
- **US Growth**: Despite overall refractive market decline, US EVO sales grew 22% Q4, driven by Fast Lane strategy and market share gains.
- **Cash Burn**: FY25 cash outflow expected due to lower revenue, but strong balance sheet ($230M+ cash) provides resilience.


STAAR Surgical Company (STAA) Q4 2024 Earnings Call Transcript

STAAR Surgical (STAA)-30 Oct 24-2024 Q3 Earnings call transcript

Staar Surgical (STAA)-7 Aug 24-2024 Q2 Earnings call transcript

Staar Surgical (STAA)-7 May 24-2024 Q1 Earnings call transcript

Staar Surgical (STAA)-26 Feb 24-2023 Q4 Earnings call transcript

Staar Surgical (STAA)-1 Nov 23-2023 Q3 Earnings call transcript

Staar Surgical (STAA)-2 Aug 23-2023 Q2 Earnings call transcript

Staar Surgical (STAA)-3 May 23-2023 Q1 Earnings call transcript

Staar Surgical (STAA)-21 Feb 23-2022 Q4 Earnings call transcript

Staar Surgical (STAA)-2 Nov 22-2022 Q3 Earnings call transcript

Staar Surgical (STAA)-11 Aug 22-2022 Q2 Earnings call transcript

Staar Surgical (STAA)-4 May 22-2022 Q1 Earnings call transcript

Staar Surgical (STAA)-24 Feb 22-2021 Q4 Earnings call transcript

Staar Surgical (STAA)-4 Nov 21-2021 Q3 Earnings call transcript

Staar Surgical (STAA)-5 Aug 21-2021 Q2 Earnings call transcript

Staar Surgical (STAA)-6 May 21-2021 Q1 Earnings call transcript

Staar Surgical (STAA)-25 Feb 21-2020 Q4 Earnings call transcript

Staar Surgical (STAA)-4 Nov 20-2020 Q3 Earnings call transcript

Staar Surgical (STAA)-5 Aug 20-2020 Q2 Earnings call transcript

Staar Surgical (STAA)-10 May 20-2020 Q1 Earnings call transcript

Staar Surgical (STAA)-26 Feb 20-2019 Q4 Earnings call transcript

Staar Surgical (STAA)-31 Oct 19-2019 Q3 Earnings call transcript

Staar Surgical (STAA)-31 Jul 19-2019 Q2 Earnings call transcript

Staar Surgical (STAA)-5 May 19-2019 Q1 Earnings call transcript

Staar Surgical (STAA)-21 Feb 19-2018 Q4 Earnings call transcript

Staar Surgical (STAA)-31 Oct 18-2018 Q3 Earnings call transcript

Staar Surgical (STAA)-1 Aug 18-2018 Q2 Earnings call transcript

Staar Surgical (STAA)-2 May 18-2018 Q1 Earnings call transcript

Staar Surgical (STAA)-28 Feb 18-2017 Q4 Earnings call transcript

Staar Surgical (STAA)-8 Nov 17-2017 Q3 Earnings call transcript

Actual											0.04	0.03	0.14	0.14	0.2	0.27	0.21	0.19	0.29	0.42	0.37	0.14	0.18	0.4	0.3	0.13	0.107	0.39	0.26	-0.5135	-0.5174	-0.3395	-0.2
Forecast											0.026	0.0075	0.0867	0.0817	0.0333	0.0814	0.1667	0.1703	0.15	0.2329	0.2	0.1348	0.0737	0.2859	0.1773	0.1788	0.0613	0.2389	0.1799	-0.0274	-0.6026	-0.5674	0.18
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+53.85%	+300.00%	+61.48%	+71.36%	+500.60%	+231.70%	+25.97%	+11.57%	+93.33%	+80.33%	+85.00%	+3.86%	+144.23%	+39.91%	+69.20%	-27.29%	+74.55%	+63.25%	+44.52%	-1774.09%	+14.14%	+40.17%	-211.11%

STAA

STAA fundamentals

STAA Q4 2025 Earnings

Earnings Call

You can ask Aime

STAA

STAA fundamentals

STAA Q4 2025 Earnings

Earnings Call

STAA Earnings Call Summary for Q4/20255:30 PM on Mar 3, 2026

STAA Earnings Call Summary for Q2/20254:00 PM on Aug 6, 2025

STAA Earnings Call Summary for Q1/20255:15 PM on May 7, 2025

STAA Earnings Call Summary for Q4/20245:00 PM on Feb 11, 2025

STAA Earnings Call Summary for Q3/20244:30 PM on Oct 30, 2024

You can ask Aime